Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
$ 18.725 0.275 (1.49%) Market Cap: 21.07 Bil Enterprise Value: 37.43 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 59/100

Q2 2022 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Jul 27, 2022 / 12:00PM GMT
Release Date Price: $9.14 (+28.37%)
Operator

Good day, and thank you for standing by. Welcome to the Teva Second Quarter Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, [Ron Mannix], Senior Vice President, Head of Investor Relations. Please go ahead.

Kevin C. Mannix
Teva Pharmaceutical Industries Limited - SVP of IR

Thank you, Sandra. Thank you, everyone, for joining us today. We all have had an opportunity to review our press release, which was issued yesterday. A copy of this press release as well as a copy of the slides being presented on this call can be found on our website at tevapharm.com. I am joined today on the call by Kare Schultz, Teva's CEO, Eliyahu Kalif, our CFO; and Sven Dethlefs, Head of North America business. We have today acquired a busy agenda. We will start the call with an update from Kare on the progress achieved on the operations front. This will be followed by cause and (inaudible) review of the second quarter business and financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot